Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04279847 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
A Phase 1 study of Myelodysplastic Syndrome and Myelofibrosis, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT04279847 is a Phase 1 study of Myelodysplastic Syndrome and Myelofibrosis that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 140 participants, below the 206-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04279847, a Phase 1 study of Myelodysplastic Syndrome and Myelofibrosis, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG INCB057643
Study Locations (20)
New York
- Nyu Langone Health - Long Island Hospital - Mineola
- Nyu Langone Laura and Isaac Perlmutter Cancer Center - New York
- Weill Medical College of Cornell University - New York
Texas
- Texas Oncology-Baylor Sammons Cancer Center - Dallas
- Md Anderson Cancer Center - Houston
- Oncology Consultants - Houston
Ohio
- University of Cincinnati Cancer Institute - Cincinnati
- Ohio State University - Columbus
Alabama
- University of Alabama At Birmingham - Birmingham
Colorado
- University of Colorado Cancer Center - Aurora
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Georgia
- Emory University-Winship Cancer Institute - Atlanta
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04279847
The ClinicalTrials.gov registry entry for NCT04279847 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (32% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT04279847 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT04279847 about?
NCT04279847 is a clinical study titled "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms". The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
What is the current status of trial NCT04279847?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2021-02-23. Estimated completion is 2027-04-30.
What conditions does trial NCT04279847 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, ET (Essential Thrombocythemia), Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome.
What interventions are being tested in trial NCT04279847?
The interventions under investigation include: Ruxolitinib (DRUG), INCB057643 (DRUG).
Who is sponsoring clinical trial NCT04279847?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04279847 being conducted?
This trial has 20 study locations across Alabama, Colorado, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.